Cor Vasa 2014, 56(3):e235-e239 | DOI: 10.1016/j.crvasa.2014.04.004
Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15
- a III. interní-kardiologická klinika, Kardiocentrum 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika
- b III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha, Česká republika
- c Kardiocentrum, Nemocnice Podlesí, Třinec, Česká republika
- d I. interní-kardiologická klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc, Česká republika
Catheter-based renal denervation (RDN) was considered as a promising method for treatment of resistant hypertension and was increasingly being used worldwide. However, there are equivocal results from only two randomized trials studying the effect of such intervention. Thus, additional data from properly designed long-term comparative trials are needed. The PRAGUE-15 trial is designed as an open, prospective, randomized multicenter trial comparing RDN versus intensified medical treatment in patients with resistant hypertension. Patients randomized to the medical treatment group will receive spironolactone in the absence of contraindications. The primary endpoint will be changes in systolic and diastolic pressure during ambulatory blood pressure monitoring (ABPM) from baseline to 6 months. Herein, we describe the trial design and methodology. The strengths of the trial include ABPM (as the objective endpoint), independent outcomes assessment, and therapeutic use of spironolactone.
Keywords: Adherence to treatment; Ambulatory blood pressure monitoring; Catheter-based renal denervation; Resistant hypertension; Spironolactone
Received: March 16, 2014; Revised: April 23, 2014; Accepted: April 27, 2014; Published: June 1, 2014 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- P.M. Kearney, M. Whelton, K. Reynolds, et al., Global burden of hypertension: analysis of worldwide data, Lancet 365 (9455) (2005) 217-223.
Go to original source...
- C.M. Lawes, S. Vander Hoorn, A. Rodgers, Global burden of blood-pressure-related disease, 2001, Lancet 371 (9623) (2008) 1513-1518.
Go to original source...
Go to PubMed...
- S. Lewington, R. Clarke, N. Qizilbash, et al., Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet 360 (9349) (2002) 1903-1913.
Go to original source...
Go to PubMed...
- D.M. Lloyd-Jones, J.C. Evans, D. Levy, Hypertension in adults across the age spectrum: current outcomes and control in the community, Journal of the American Medical Association 294 (4) (2005) 466-472.
Go to original source...
Go to PubMed...
- D.A. Calhoun, D. Jones, S. Textor, et al., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Circulation 117 (25) (2008) e510-e526.
Go to original source...
Go to PubMed...
- G. Mancia, R. Fagard, K. Nirkiewicz, et al., 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), European Heart Journal 34 (28) (2013) 2159-2219.
Go to original source...
Go to PubMed...
- Y. Huan, D.L. Cohen, Renal denervation: a potential new treatment for severe hypertension, Clinical Cardiology 36 (1) (2013) 10-14.
Go to original source...
Go to PubMed...
- M.D. Esler, H. Krum, P.A. Sobotka, et al., Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial, Lancet 376 (9756) (2010) 1903-1909.
Go to original source...
Go to PubMed...
- D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, et al., A controlled trial of renal denervation for resistant hypertension, New England Journal of Medicine 370 (15) (2014) 1393-1401.
Go to original source...
Go to PubMed...
- P. Widimsky, J. Filipovsky, J. Widimsky Jr., et al., Expert consensus statement of the Czech Society of Cardiology and the Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech Republic, Cor et Vasa 54 (2012) e108-e112.
Go to original source...
- J. Vaclavik, R. Sedlak, M. Plachy, et al., Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial, Hypertension 57 (6) (2011) 1069-1075.
Go to original source...
Go to PubMed...
- J.W. Funder, R.M. Carrey, C. Fardella, et al., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline, Journal of Clinical Endocrinology and Metabolism 93 (9) (2008) 3266-3281.
Go to original source...
Go to PubMed...
- B. Strauch, O. Petrak, T. Zelinka, et al., Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis, Journal of Hypertension 31 (12) (2013) 2455-2461.
Go to original source...
Go to PubMed...
- O. Gonzalez, R.M. Alonso, N. Ferreirós, et al., LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 878 (28) (2010) 2685-2692.
Go to original source...
Go to PubMed...
- L. Chytil, B. Strauch, J. Cvacka, et al., Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 878 (30) (2010) 3167-3173.
Go to original source...
- F. Mahfoud, C. Ukena, R.E. Schmieder, et al., Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension, Circulation 128 (2) (2013) 132-140.
Go to original source...
Go to PubMed...
- F. de Souza, E. Muxfeldt, R. Fiszman, et al., Efficacy of spironolactone therapy in patients with true resistant hypertension, Hypertension 55 (1) (2010) 147-152.
Go to original source...
Go to PubMed...
- S.G. Worthley, C.P. Tsioufis, M.I. Worthley, et al., Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial, European Heart Journal 34 (28) (2013) 2132-2140.
Go to original source...
Go to PubMed...
- Symplicity HTN-1 Investigators, Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months, Hypertension 57 (5) (2011) 911-917.
Go to PubMed...
- P. Widimsky, P. Osmancik, J. Widimsky Jr., et al., Renal denervation: the hope for patients with refractory hypertension? Cor et Vasa 53 (2011) 517-521.
Go to original source...
- G. Grassi, R. Facchetti, G. Seravalle, et al., Home and ambulatory blood pressure in resistant hypertension, EuroIntervention 9 (Suppl. R) (2013) R35-R41.
Go to original source...
Go to PubMed...
- A. Persu, M. Azizi, M. Burnier, et al., Residual effect of renal denervation in patients with truly resistant hypertension, Hypertension 62 (3) (2013) 450-452.
Go to original source...
Go to PubMed...
- D.E. Kandzari, D.L. Bhatt, P.A. Sobotka, et al., Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial, Clinical Cardiology 35 (9) (2012) 528-535.
Go to original source...
Go to PubMed...
- R. Sega, R. Facchetti, M. Bombelli, et al., Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study, Circulation 111 (14) (2005) 1777-1783.
Go to original source...
Go to PubMed...